Quantification of the cellular content of platelet-rich plasma harvested after injection of filgrastim versus pegfilgrastim biosimilars: a prospective, single-center, crossover study
Introduction: Hematopoietic stem cells (HSCs) appear in peripheral blood (PB) following mobilization due to external events or pharmaceutical agents like filgrastim and pegfilgrastim. Concentration of these into platelet-rich plasma (PRP) can be used in orthopedics. Objectives: This prospective, sin...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Journal of Cartilage & Joint Preservation |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667254524000477 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850259847421886464 |
|---|---|
| author | Mohammadreza Abbasian Eric Branch Ali Parsa Jessica Truett Joshua J. Cook Charlkesha A. Rahming Adam W. Anz |
| author_facet | Mohammadreza Abbasian Eric Branch Ali Parsa Jessica Truett Joshua J. Cook Charlkesha A. Rahming Adam W. Anz |
| author_sort | Mohammadreza Abbasian |
| collection | DOAJ |
| description | Introduction: Hematopoietic stem cells (HSCs) appear in peripheral blood (PB) following mobilization due to external events or pharmaceutical agents like filgrastim and pegfilgrastim. Concentration of these into platelet-rich plasma (PRP) can be used in orthopedics. Objectives: This prospective, single-center, controlled laboratory study aimed to compare safety profiles of filgrastim and pegfilgrastim administration, quantifying the cellular content of PRP derived from PB post-administration. We hypothesized comparable rates and severity of adverse events (AEs) among participants, along with similar cellular content in the PRP products. Methods: Ten healthy male participants underwent a crossover design with 2 interventions separated by a washout period. PB was collected before and after each intervention, producing PRP for cellular comparison in vitro. AEs were monitored for severity and frequency throughout study. Results: Significant AEs for filgrastim included fatigue (36%), myalgia (36%), and back pain (9.1%), compared to pegfilgrastim, which included myalgia (31%), fatigue (23%), and back pain (23%). There were no significant differences between AE occurrences (P = .49) nor relationship to study drug (P > .99). Regarding total nucleated cell count (TNC), statistical significance was found in TNC count (P = .010) and TNC concentration (P = .004). All PRP products expressed high levels (>88%) of hematopoietic progenitor cell/HSC-specific CD45+, CD34+, CD45dim+, and hematopoietic progenitor cell/HSC+ markers. Conclusions: This study demonstrated that filgrastim and pegfilgrastim administration appear safe. Pegfilgrastim is equivalent to filgrastim for the mobilization of white blood cells and cells expressing hematopoietic cell-surface markers into the PB and consequently, into the derived PRP product. Clinical relevance: This study presents pegfilgrastim as a single-injection alternative to filgrastim for the mobilization of HSCs into the PB and subsequent PB-derived PRP, which is more convenient and less invasive for patients. |
| format | Article |
| id | doaj-art-689612c654dd4d18bfea3cfa89ac0331 |
| institution | OA Journals |
| issn | 2667-2545 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Cartilage & Joint Preservation |
| spelling | doaj-art-689612c654dd4d18bfea3cfa89ac03312025-08-20T01:55:46ZengElsevierJournal of Cartilage & Joint Preservation2667-25452024-12-014410021110.1016/j.jcjp.2024.100211Quantification of the cellular content of platelet-rich plasma harvested after injection of filgrastim versus pegfilgrastim biosimilars: a prospective, single-center, crossover studyMohammadreza Abbasian0Eric Branch1Ali Parsa2Jessica Truett3Joshua J. Cook4Charlkesha A. Rahming5Adam W. Anz6Andrews Institute Center for Regenerative Medicine, Department of Research, Andrews Research & Education Foundation (AREF), Gulf Breeze, FL, USAAndrews Institute Center for Regenerative Medicine, Department of Research, Andrews Research & Education Foundation (AREF), Gulf Breeze, FL, USAAndrews Institute Center for Regenerative Medicine, Department of Research, Andrews Research & Education Foundation (AREF), Gulf Breeze, FL, USAAndrews Institute Center for Regenerative Medicine, Department of Research, Andrews Research & Education Foundation (AREF), Gulf Breeze, FL, USAAndrews Institute Center for Regenerative Medicine, Department of Research, Andrews Research & Education Foundation (AREF), Gulf Breeze, FL, USAAndrews Institute Center for Regenerative Medicine, Department of Research, Andrews Research & Education Foundation (AREF), Gulf Breeze, FL, USAAdam W. Anz, Andrews Research & Education Foundation (AREF), 1020 Gulf Breeze Parkway, Gulf Breeze, FL 32561.; Andrews Institute Center for Regenerative Medicine, Department of Research, Andrews Research & Education Foundation (AREF), Gulf Breeze, FL, USAIntroduction: Hematopoietic stem cells (HSCs) appear in peripheral blood (PB) following mobilization due to external events or pharmaceutical agents like filgrastim and pegfilgrastim. Concentration of these into platelet-rich plasma (PRP) can be used in orthopedics. Objectives: This prospective, single-center, controlled laboratory study aimed to compare safety profiles of filgrastim and pegfilgrastim administration, quantifying the cellular content of PRP derived from PB post-administration. We hypothesized comparable rates and severity of adverse events (AEs) among participants, along with similar cellular content in the PRP products. Methods: Ten healthy male participants underwent a crossover design with 2 interventions separated by a washout period. PB was collected before and after each intervention, producing PRP for cellular comparison in vitro. AEs were monitored for severity and frequency throughout study. Results: Significant AEs for filgrastim included fatigue (36%), myalgia (36%), and back pain (9.1%), compared to pegfilgrastim, which included myalgia (31%), fatigue (23%), and back pain (23%). There were no significant differences between AE occurrences (P = .49) nor relationship to study drug (P > .99). Regarding total nucleated cell count (TNC), statistical significance was found in TNC count (P = .010) and TNC concentration (P = .004). All PRP products expressed high levels (>88%) of hematopoietic progenitor cell/HSC-specific CD45+, CD34+, CD45dim+, and hematopoietic progenitor cell/HSC+ markers. Conclusions: This study demonstrated that filgrastim and pegfilgrastim administration appear safe. Pegfilgrastim is equivalent to filgrastim for the mobilization of white blood cells and cells expressing hematopoietic cell-surface markers into the PB and consequently, into the derived PRP product. Clinical relevance: This study presents pegfilgrastim as a single-injection alternative to filgrastim for the mobilization of HSCs into the PB and subsequent PB-derived PRP, which is more convenient and less invasive for patients.http://www.sciencedirect.com/science/article/pii/S2667254524000477BiosimilarsFilgrastimPegfilgrastimPlatelet-rich plasma |
| spellingShingle | Mohammadreza Abbasian Eric Branch Ali Parsa Jessica Truett Joshua J. Cook Charlkesha A. Rahming Adam W. Anz Quantification of the cellular content of platelet-rich plasma harvested after injection of filgrastim versus pegfilgrastim biosimilars: a prospective, single-center, crossover study Journal of Cartilage & Joint Preservation Biosimilars Filgrastim Pegfilgrastim Platelet-rich plasma |
| title | Quantification of the cellular content of platelet-rich plasma harvested after injection of filgrastim versus pegfilgrastim biosimilars: a prospective, single-center, crossover study |
| title_full | Quantification of the cellular content of platelet-rich plasma harvested after injection of filgrastim versus pegfilgrastim biosimilars: a prospective, single-center, crossover study |
| title_fullStr | Quantification of the cellular content of platelet-rich plasma harvested after injection of filgrastim versus pegfilgrastim biosimilars: a prospective, single-center, crossover study |
| title_full_unstemmed | Quantification of the cellular content of platelet-rich plasma harvested after injection of filgrastim versus pegfilgrastim biosimilars: a prospective, single-center, crossover study |
| title_short | Quantification of the cellular content of platelet-rich plasma harvested after injection of filgrastim versus pegfilgrastim biosimilars: a prospective, single-center, crossover study |
| title_sort | quantification of the cellular content of platelet rich plasma harvested after injection of filgrastim versus pegfilgrastim biosimilars a prospective single center crossover study |
| topic | Biosimilars Filgrastim Pegfilgrastim Platelet-rich plasma |
| url | http://www.sciencedirect.com/science/article/pii/S2667254524000477 |
| work_keys_str_mv | AT mohammadrezaabbasian quantificationofthecellularcontentofplateletrichplasmaharvestedafterinjectionoffilgrastimversuspegfilgrastimbiosimilarsaprospectivesinglecentercrossoverstudy AT ericbranch quantificationofthecellularcontentofplateletrichplasmaharvestedafterinjectionoffilgrastimversuspegfilgrastimbiosimilarsaprospectivesinglecentercrossoverstudy AT aliparsa quantificationofthecellularcontentofplateletrichplasmaharvestedafterinjectionoffilgrastimversuspegfilgrastimbiosimilarsaprospectivesinglecentercrossoverstudy AT jessicatruett quantificationofthecellularcontentofplateletrichplasmaharvestedafterinjectionoffilgrastimversuspegfilgrastimbiosimilarsaprospectivesinglecentercrossoverstudy AT joshuajcook quantificationofthecellularcontentofplateletrichplasmaharvestedafterinjectionoffilgrastimversuspegfilgrastimbiosimilarsaprospectivesinglecentercrossoverstudy AT charlkeshaarahming quantificationofthecellularcontentofplateletrichplasmaharvestedafterinjectionoffilgrastimversuspegfilgrastimbiosimilarsaprospectivesinglecentercrossoverstudy AT adamwanz quantificationofthecellularcontentofplateletrichplasmaharvestedafterinjectionoffilgrastimversuspegfilgrastimbiosimilarsaprospectivesinglecentercrossoverstudy |